Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Hui Wang
Southern University of Science and Technology - Shenzhen Third People's Hospital
Shenzhen
China
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
154
TOTAL CITATIONS
2
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Efficacy and Safety of Long Acting HIV Fusion Inhibitor Albuvirtide in Antiretroviral-Experienced Adults with HIV-1: Interim 48 Week Results from the Randomized, Controlled, Phase 3 Trial, Non-Inferiority TALENT Study
Number of pages: 27
Posted: 08 Jan 2019
Hao Wu
,
Cheng Yao
,
Bin Su
,
Hongzhou Lu
,
Yongtao Sun
,
Min Wang
, Hui Wang,
Yuhuang Zheng
,
Biao Zhu
,
Jianhua Yu
,
Min Zhao
,
Wenhui Lun
,
Wei Xia
,
Meixia Wang
,
Qingshan Zheng
,
Haiyan Peng
,
Rongjian Lu
,
Jianhua Hu
,
Hui Xing
,
Yiming Shao
,
Qingxia Zhao
,
Weiping Cai
,
Tong Zhang
,
Dong Xie
and
TALENT Study Team
Capital Medical University - Beijing YouAn Hospital, Frontier Biotechnologies Inc., Capital Medical University, Fudan University - Department of Radiology, Government of the People's Republic of China - Tangdu Hospital, The First Hospital of Changsha, Southern University of Science and Technology - Shenzhen Third People's Hospital, Central South University - Second Xiangya Hospital, Zhejiang University - First Affiliated Hospital, Zhejiang Chinese Medical University - Xixi Hospital of Hangzhou, Government of the People's Republic of China - 302 Military Hospital, Capital Medical University - Beijing Ditan Hospital, Capital Medical University - Beijing YouAn Hospital, Capital Medical University - Center for Infectious Diseases, Shanghai University of Traditional Chinese Medicine, Beijing Co-CRO Medical Development Co., Ltd., Frontier Biotechnologies Inc., Frontier Biotechnologies Inc., Chinese Center for Disease Control and Prevention (China CDC) - National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC) - National Center for AIDS/STD Control and Prevention, Zhengzhou University, Guangzhou Medical University - Guangzhou Eighth People's Hospital, Capital Medical University - Clinical and Research Center for Infectious Diseases, Frontier Biotechnologies Inc. and Independent
Downloads
154
(482,968)
Citation
2
View PDF
Download
Abstract:
HIV; fusion inhibitor; albuvirtide; LPV/r; non-inferiority; phase 3 clinical trial
Feedback